会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Protein Kinase Targeted Therapeutics
    • 蛋白激酶靶向治疗
    • US20110166153A1
    • 2011-07-07
    • US13034411
    • 2011-02-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • A61K31/501A61P29/00
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1δ以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如,CK1δ, 和上游和下游蛋白激酶)。
    • 5. 发明授权
    • Protein kinase targeted therapeutics
    • 蛋白激酶靶向治疗
    • US07919485B2
    • 2011-04-05
    • US12566153
    • 2009-09-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • A61K31/33A61K31/50C07D401/00
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1δ以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如,CK1δ, 和上游和下游蛋白激酶)。
    • 6. 发明授权
    • Protein kinase targeted therapeutics
    • 蛋白激酶靶向治疗
    • US08188096B2
    • 2012-05-29
    • US13034411
    • 2011-02-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • C07D239/42
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1δ以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如,CK1δ, 和上游和下游蛋白激酶)。
    • 7. 发明申请
    • Protein Kinase Targeted Therapeutics
    • 蛋白激酶靶向治疗
    • US20100016587A1
    • 2010-01-21
    • US12566153
    • 2009-09-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • C07D401/04
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1delta以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如CK1delta, 和上游和下游蛋白激酶)。